
Europe Pharmacogenomics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Technology (PCR, Sequencing, Microarray, Gel Electrophoresis, Mass Spectrometry, and Others), Application (Drug Discovery, Oncology, Neurology and Psychiatry, Pain
Description
Europe Pharmacogenomics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Technology (PCR, Sequencing, Microarray, Gel Electrophoresis, Mass Spectrometry, and Others), Application (Drug Discovery, Oncology, Neurology and Psychiatry, Pain Management, Cardiovascular Diseases, and Others), and End User (Hospitals and Clinics, Biopharmaceutical Companies, CROs and CDMOs, and Others)
The Europe pharmacogenomics market is expected to reach US$ 3,874.31 million by 2028 from US$ 1,962.48 million in 2021. It is estimated to grow at a CAGR of 10.2% from 2021 to 2028.
The key factors driving the growth of this market are the increasing prevalence of chronic diseases, the surge in demand for precision medicines, and the rise in funding for pharmacogenomic research activities. However, the shortage of skilled professionals is expected to restrict the market growth during the forecast period.
Genomic sequencing is increasingly used in clinical practice, and over the next five years, genomic data from over 60 million patients are expected to be generated within the healthcare system. Pharmacogenomics is rapidly transitioning into clinical practice, and implementation into healthcare systems supported by government investment is totaling over US$ 4 billion in at least 14 countries. These national genomic-medicine initiatives drive transformative change under real-life conditions while simultaneously addressing barriers against implementation and gathering evidence for broader adoption.
The UK has announced the world’s largest genome project as a part of the EURO200 million public-private collaboration between charities and pharma. The country has already developed the largest genome database in the world through the 100,000 genome projects led by Innovate UK as a part of the UK Research and Innovation. It will fund researchers and industries to combine data and real-world evidence from the UK healthcare services and create new products and services that diagnose diseases more efficiently.
In November 2018, Stilla Technologies announced it had completed an US$ 18.3 million (EUR 16 million) Series A financing round led by Illumina Ventures. The company plans to use the funds to commercialize its Naica digital PCR system and develop clinical applications.
The continuous funding by manufacturers and governments in the genomics field is driving the Europe pharmacogenomics market.
Europe Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Mn)
EUROPE PHARMACOGENOMICS MARKET SEGMENTATION
By Technology
Hospitals & Clinics Biopharmaceutical Companies CROs and CDMOs Others By Application
PCRSequencing Microarraygel electrophoresismass spectrometry Others By End User
Drugs Discovery Oncology Neurological & Psychiatry Pain Management Cardiovascular Others By Country
Germany UKFrance Italy Spain Rest of Europe Company Profiles
Abbott F. HOFFMANN-LA ROCHE LTD.Oxford Nanopore Technologies THERMO FISHER SCIENTIFIC INC.Illumina, Inc.QIAGENAgilent Technologies, Inc.Myriad Genetics, Inc.
Reasons to Buy
Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe pharmacogenomics market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the Europe pharmacogenomics market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
The Europe pharmacogenomics market is expected to reach US$ 3,874.31 million by 2028 from US$ 1,962.48 million in 2021. It is estimated to grow at a CAGR of 10.2% from 2021 to 2028.
The key factors driving the growth of this market are the increasing prevalence of chronic diseases, the surge in demand for precision medicines, and the rise in funding for pharmacogenomic research activities. However, the shortage of skilled professionals is expected to restrict the market growth during the forecast period.
Genomic sequencing is increasingly used in clinical practice, and over the next five years, genomic data from over 60 million patients are expected to be generated within the healthcare system. Pharmacogenomics is rapidly transitioning into clinical practice, and implementation into healthcare systems supported by government investment is totaling over US$ 4 billion in at least 14 countries. These national genomic-medicine initiatives drive transformative change under real-life conditions while simultaneously addressing barriers against implementation and gathering evidence for broader adoption.
The UK has announced the world’s largest genome project as a part of the EURO200 million public-private collaboration between charities and pharma. The country has already developed the largest genome database in the world through the 100,000 genome projects led by Innovate UK as a part of the UK Research and Innovation. It will fund researchers and industries to combine data and real-world evidence from the UK healthcare services and create new products and services that diagnose diseases more efficiently.
In November 2018, Stilla Technologies announced it had completed an US$ 18.3 million (EUR 16 million) Series A financing round led by Illumina Ventures. The company plans to use the funds to commercialize its Naica digital PCR system and develop clinical applications.
The continuous funding by manufacturers and governments in the genomics field is driving the Europe pharmacogenomics market.
Europe Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Mn)
EUROPE PHARMACOGENOMICS MARKET SEGMENTATION
By Technology
Hospitals & Clinics Biopharmaceutical Companies CROs and CDMOs Others By Application
PCRSequencing Microarraygel electrophoresismass spectrometry Others By End User
Drugs Discovery Oncology Neurological & Psychiatry Pain Management Cardiovascular Others By Country
Germany UKFrance Italy Spain Rest of Europe Company Profiles
Abbott F. HOFFMANN-LA ROCHE LTD.Oxford Nanopore Technologies THERMO FISHER SCIENTIFIC INC.Illumina, Inc.QIAGENAgilent Technologies, Inc.Myriad Genetics, Inc.
Reasons to Buy
Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe pharmacogenomics market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the Europe pharmacogenomics market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Table of Contents
171 Pages
- 1. Introduction
- 1.1 Scope of the Study
- 1.2 The Insight Partners Research Report Guidance
- 1.3 Market Segmentation
- 1.3.1 Europe Pharmacogenomics Market – By Technology
- 1.3.2 Europe Pharmacogenomics Market – By Application
- 1.3.3 Europe Pharmacogenomics Market – By End User
- 1.3.4 Europe Pharmacogenomics Market – By Country
- 2. Key Takeaways
- 3. Research Methodology
- 3.1 Coverage
- 3.2 Secondary Research
- 3.3 Primary Research
- 4. Pharmacogenomics Market – Market Landscape
- 4.1 Overview
- 4.2 PEST Analysis
- 4.2.1 Europe PEST Analysis
- 4.3 Experts Opinion
- 5. Pharmacogenomics Market – Key Market Dynamics
- 5.1 Market Drivers
- 5.1.1 Increasing Prevalence of Chronic Diseases
- 5.1.2 Growing Funding for Pharmacogenomics
- 5.2 Market Restraints
- 5.2.1 Lack of Skilled Professionals
- 5.3 Market Opportunities
- 5.3.1 Increasing Demand for Third Generation Sequencing
- 5.4 Future Trends
- 5.4.1 Increasing Demand for Personalized Medicines
- 6. Pharmacogenomics Market–Europe Analysis
- 6.1 Europe Pharmacogenomics Market Revenue Forecast and Analysis
- 7. Pharmacogenomics Market Revenue and Forecasts To 2028 – Technology
- 7.1 Overview
- 7.2 Europe Pharmacogenomics Market Share by Technology - 2021 & 2028 (%)
- 7.3 Polymerase Chain Reaction
- 7.3.1 Overview
- 7.3.2 Polymerase Chain Reaction: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
- 7.3.3 Real Time PCR
- 7.3.3.1 Overview
- 7.3.3.2 Real Time PCR: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
- 7.3.4 Standard PCR
- 7.3.4.1 Overview
- 7.3.4.2 Standard PCR: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
- 7.3.5 Digital PCR
- 7.3.5.1 Overview
- 7.3.5.2 Digital PCR: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
- 7.4 Sequencing
- 7.4.1 Overview
- 7.4.2 Sequencing: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
- 7.5 Microarray
- 7.5.1 Overview
- 7.5.2 Microarray: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
- 7.6 Gel Electrophoresis
- 7.6.1 Overview
- 7.6.2 Gel Electrophoresis: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
- 7.7 Mass Spectrometry
- 7.7.1 Overview
- 7.7.2 Mass Spectrometry: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
- 7.8 Others
- 7.8.1 Overview
- 7.8.2 Others: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
- 8. Global Pharmacogenomics Market Revenue and Forecasts To 2028– by Application
- 8.1 Overview
- 8.2 Europe Pharmacogenomics Market Share by Application- 2021 & 2028 (%)
- 8.3 Drug Discovery
- 8.3.1 Overview
- 8.3.2 Drug Discovery: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
- 8.4 Oncology
- 8.4.1 Overview
- 8.4.2 Oncology: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
- 8.5 Neurology & Psychiatry
- 8.5.1 Overview
- 8.5.2 Neurology & Psychiatry: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
- 8.6 Pain Management
- 8.6.1 Overview
- 8.6.2 Pain Management: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
- 8.7 Cardiovascular Disease
- 8.7.1 Overview
- 8.7.2 Cardiovascular Disease: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
- 8.8 Others
- 8.8.1 Overview
- 8.8.2 Others: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
- 9. Pharmacogenomics Market Revenue and Forecasts To 2028 – End User
- 9.1 Overview
- 9.2 Europe Pharmacogenomics Market Share by End User - 2021 & 2028 (%)
- 9.3 Hospitals and Clinics
- 9.3.1 Overview
- 9.3.2 Hospitals and Clinics: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
- 9.4 Biopharmaceutical Companies
- 9.4.1 Overview
- 9.4.2 Biopharmaceuticals Companies: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
- 9.5 CROs and CDMOs
- 9.5.1 Overview
- 9.5.2 CROs and CDMOs: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
- 9.6 Others
- 9.6.1 Overview
- 9.6.2 Others: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
- 10. Pharmacogenomics Market Revenue and Forecasts to 2028 –Country Analysis
- 10.1 Europe: Pharmacogenomics Market
- 10.1.1 Overview
- 10.1.2 Europe: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
- 10.1.3 Europe: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million)
- 10.1.3.1 Europe: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million)
- 10.1.4 Europe: Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million)
- 10.1.5 Europe: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million)
- 10.1.6 Europe: Pharmacogenomics Market, by Country, 2021 & 2028 (%)
- 10.1.6.1 Germany: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
- 10.1.6.1.1 Overview
- 10.1.6.1.2 Germany: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
- 10.1.6.1.3 Germany: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million)
- 10.1.6.1.3.1 Germany: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million)
- 10.1.6.1.4 Germany: Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million)
- 10.1.6.1.5 Germany: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million)
- 10.1.6.2 France: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
- 10.1.6.2.1 Overview
- 10.1.6.2.2 France: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
- 10.1.6.2.3 France: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million)
- 10.1.6.2.3.1 France: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million)
- 10.1.6.2.4 France: Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million)
- 10.1.6.2.5 France: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million)
- 10.1.6.3 UK: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
- 10.1.6.3.1 Overview
- 10.1.6.3.2 UK: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
- 10.1.6.3.3 UK: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million)
- 10.1.6.3.3.1 UK: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million)
- 10.1.6.3.4 UK: Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million)
- 10.1.6.3.5 UK: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million)
- 10.1.6.4 Italy: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
- 10.1.6.4.1 Overview
- 10.1.6.4.2 Italy: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
- 10.1.6.4.3 Italy: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million)
- 10.1.6.4.3.1 Italy: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million)
- 10.1.6.4.4 Italy: Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million)
- 10.1.6.4.5 Italy: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million)
- 10.1.6.5 Spain: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
- 10.1.6.5.1 Overview
- 10.1.6.5.2 Spain: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
- 10.1.6.5.3 Spain: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million)
- 10.1.6.5.3.1 Spain: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million)
- 10.1.6.5.4 Spain: Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million)
- 10.1.6.5.5 Spain: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million)
- 10.1.6.6 Rest of Europe: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
- 10.1.6.6.1 Overview
- 10.1.6.6.2 Rest of Europe: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
- 10.1.6.6.3 Rest of Europe: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million)
- 10.1.6.6.3.1 Rest of Europe: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million)
- 10.1.6.6.4 Rest of Europe: Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million)
- 10.1.6.6.5 Rest of Europe: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million)
- 11. Impact of COVID-19 Pandemic on Europe Pharmacogenomics Market
- 11.1 Europe: Impact Assessment of COVID-19 Pandemic
- 12. Industry Landscape
- 12.1 Overview
- 12.2 Organic Developments
- 12.2.1 Overview
- 12.3 Inorganic Developments
- 12.3.1 Overview
- 13. Company Profiles
- 13.1 Abbott
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
- 13.2 F. HOFFMANN-LA ROCHE LTD.
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
- 13.3 Oxford Nanopore Technologies
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
- 13.4 THERMO FISHER SCIENTIFIC INC.
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
- 13.5 Illumina, Inc.
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
- 13.6 QIAGEN
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
- 13.7 Agilent Technologies, Inc.
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
- 13.8 Myriad Genetics, Inc.
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
- 14. Appendix
- 14.1 About The Insight Partners
- 14.2 Glossary of Terms
- List of Tables
- Table 1. Europe: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million)
- Table 2. Europe: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million)
- Table 3. Europe: Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million)
- Table 4. Europe: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million)
- Table 5. Germany: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million)
- Table 6. Germany: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million)
- Table 7. Germany: Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million)
- Table 8. Germany: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million)
- Table 9. France: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million)
- Table 10. France: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million)
- Table 11. France: Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million)
- Table 12. France: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million)
- Table 13. UK: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million)
- Table 14. UK: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million)
- Table 15. UK: Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million)
- Table 16. UK: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million)
- Table 17. Italy: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million)
- Table 18. Italy: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million)
- Table 19. Italy: Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million)
- Table 20. Italy: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million)
- Table 21. Spain: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million)
- Table 22. Spain: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million)
- Table 23. Spain: Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million)
- Table 24. Spain: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million)
- Table 25. Rest of Europe: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million)
- Table 26. Rest of Europe: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million)
- Table 27. Rest of Europe: Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million)
- Table 28. Rest of Europe: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million)
- Table 29. Organic Developments Done By Companies
- Table 30. Inorganic Developments Done By Companies
- Table 31. Glossary of Terms
- List of Figures
- Figure 1. Pharmacogenomics Market Segmentation
- Figure 2. Pharmacogenomics Market, By Country
- Figure 3. Europe Pharmacogenomics Market Overview
- Figure 4. PCR Segment Held Largest Share of Technology Segment in Pharmacogenomics Market
- Figure 5. Pharmacogenomics Market- Leading Country Markets (US$ Million)
- Figure 6. Europe: PEST Analysis
- Figure 7. Experts Opinion
- Figure 8. Europe Pharmacogenomics Market– Revenue Forecast and Analysis – 2021 - 2028
- Figure 9. Europe Pharmacogenomics Market Share by Segment - 2021 & 2028 (%)
- Figure 10. Polymerase Chain Reaction: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
- Figure 11. Real Time PCR: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
- Figure 12. Standard PCR: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
- Figure 13. Digital PCR: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
- Figure 14. Sequencing: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
- Figure 15. Microarray: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
- Figure 16. Gel Electrophoresis: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
- Figure 17. Mass Spectrometry: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
- Figure 18. Others: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
- Figure 19. Europe Pharmacogenomics Market Share by Application- 2021 & 2028 (%)
- Figure 20. Drug Discovery: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
- Figure 21. Oncology: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
- Figure 22. Neurology & Psychiatry: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
- Figure 23. Pain Management: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
- Figure 24. Cardiovascular Disease: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
- Figure 25. Others: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
- Figure 26. Europe Pharmacogenomics Market Share by End User - 2021 & 2028 (%)
- Figure 27. Hospital and Clinics: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
- Figure 28. Biopharmaceutical Companies: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
- Figure 29. CROs and CDMOs: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
- Figure 30. Others: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
- Figure 31. Europe: Pharmacogenomics Market, by Key Country – Revenue (2021) (US$ Million)
- Figure 32. Europe: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
- Figure 33. Europe: Pharmacogenomics Market, by Country, 2021 & 2028 (%)
- Figure 34. Germany: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
- Figure 35. France: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
- Figure 36. UK: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
- Figure 37. Italy: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
- Figure 38. Spain: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
- Figure 39. Rest of Europe: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
- Figure 40. Impact of COVID-19 Pandemic on Sequencing Reagents Market in European Countries
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.